Tetrahydrocurcumin compositions, methods of making, and methods of using the same
US-12115138-B2 · Oct 15, 2024 · US
US10959966B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10959966-B2 |
| Application number | US-201515115132-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 30, 2015 |
| Priority date | Jan 30, 2014 |
| Publication date | Mar 30, 2021 |
| Grant date | Mar 30, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The potency of a series of Hexamethylene bis-acetamide (HMBA) derivatives of formula I, that induce Hexamethylene bis-acetamide inducible protein 1 (HEXIM1) was determined in cancer cells. The method of inducing HEXIM1 expression and cell differentiation in cancer and HIV cells are disclosed. Optimization of HMBA analogs that are symmetrical and unsymmetrical are also discussed.
Opening claim text (preview).
Having described the invention, we claim: 1. A method of inducing hexamethylene bis-acetamide inducible protein 1 (HEXIM1) expression in at least one of breast cancer cells and/or prostate cancer cells of a subject, comprising: administering to the cancer cells of the subject a compound having the formula: R 7 is selected from the group consisting of substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, heteroaryl or heterocyclyl containing from 5-14 ring atoms, C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, and (—O-acyl); R 8 is a linear or branched C 1 -C 12 alkyl group; and pharmaceutically acceptable salts thereof. 2. The method of claim 1 , wherein the compound is administered in vitro, in vivo and/or ex vivo to the breast cancer cells and/or prostate cancer cells of the subject. 3. The method of claim 1 , wherein the compound has the formula: wherein n 1 is 1-7, R 9 is an electron donating or withdrawing group selected from the group consisting of OH, OMe, OAc, CN, NO 2 , halo, —(CH 2 )n 3 CH 3 (n 2 =0-7), phenyl, benzyl, SO 2 , SO 3 , alkylsulfonyl, amine, alkylamino, and carboxyl, and pharmaceutically acceptable salts thereof. 4. The method of claim 1 , wherein the compound has the formula:
Amides, e.g. hydroxamic acids · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.